Recent News

• 01.08.2026 - Cellectis Announces 2026 Strategy and Catalysts
• 12.15.2025 - Cellectis Announces Arbitral Decision in Dispute with Servier
• 12.08.2025 - ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
• 11.19.2025 - Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
• 11.07.2025 - Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.03.2025 - Cellectis to Present a Development Update for eti-cel at ASH 2025

Recent Filings

• 01.08.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.08.2026 - EX-99.1 EX-99.1
• 12.15.2025 - EX-99.1 EX-99.1
• 12.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.12.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 12.08.2025 - EX-99.1 EX-99.1
• 12.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.19.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.19.2025 - EX-99.1 EX-99.1